Seelos Therapeutics Valuation
| SEEL Stock | USD 0.39 0.11 22.00% |
Seelos Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Seelos Therapeutics from inspecting the company fundamentals such as Return On Equity of -5.84, operating margin of (8.35) %, and Shares Outstanding of 581 K as well as reviewing its technical indicators and probability of bankruptcy. . In general, most investors recommend picking up undervalued stocks and discarding overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.
Overvalued
Today
Please note that Seelos Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Seelos Therapeutics is based on 3 months time horizon. Increasing Seelos Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Seelos otc stock is determined by what a typical buyer is willing to pay for full or partial control of Seelos Therapeutics. Since Seelos Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Seelos OTC Stock. However, Seelos Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.39 | Real 0.37 | Hype 0.39 | Naive 0.003761 |
The intrinsic value of Seelos Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Seelos Therapeutics' stock price.
Estimating the potential upside or downside of Seelos Therapeutics helps investors to forecast how Seelos otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Seelos Therapeutics more accurately as focusing exclusively on Seelos Therapeutics' fundamentals will not take into account other important factors: Seelos Therapeutics Total Value Analysis
Seelos Therapeutics is at this time forecasted to have valuation of 10.45 M with market capitalization of 743.68 K, debt of 14.23 M, and cash on hands of 41.25 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Seelos Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.45 M | 743.68 K | 14.23 M | 41.25 M |
Seelos Therapeutics Investor Information
The company recorded earning per share (EPS) of 351.04. Seelos Therapeutics last dividend was issued on the 24th of January 2019. The entity had 1:16 split on the 27th of September 2024. Based on the key indicators related to Seelos Therapeutics' liquidity, profitability, solvency, and operating efficiency, Seelos Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Seelos Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Seelos Therapeutics has an asset utilization ratio of 40.66 percent. This suggests that the OTC Stock is making $0.41 for each dollar of assets. An increasing asset utilization means that Seelos Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Seelos Therapeutics Ownership Allocation
About 95.05 % of Seelos Therapeutics outstanding shares are held by general public with 0.49 (%) owned by insiders and only 4.46 % by institutional holders.Seelos Therapeutics Profitability Analysis
The company reported the previous year's revenue of 2.2 M. Net Loss for the year was (37.88 M) with loss before overhead, payroll, taxes, and interest of (46.65 M).About Seelos Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Seelos Therapeutics. In general, an absolute valuation paradigm, as applied to this otc stock, attempts to find the value of Seelos Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Seelos Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Seelos Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Seelos Therapeutics. We calculate exposure to Seelos Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Seelos Therapeutics's related companies.Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York. Seelos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people.
8 Steps to conduct Seelos Therapeutics' Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Seelos Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Seelos Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Seelos Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Seelos Therapeutics' revenue streams: Identify Seelos Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Seelos Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Seelos Therapeutics' growth potential: Evaluate Seelos Therapeutics' management, business model, and growth potential.
- Determine Seelos Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Seelos Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Seelos Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Seelos Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 4.9 M |
Other Information on Investing in Seelos OTC Stock
Seelos Therapeutics financial ratios help investors to determine whether Seelos OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Seelos with respect to the benefits of owning Seelos Therapeutics security.